The DEA has shared its final production quotas for research drugs for 2023 and is now aiming further than manufacturing targets for many psychedelic compounds already increases a lot In respect of 2022 initially proposed, informed of Marijuana moment.
Compounds include marijuana, MDMA, psilocybin, LSD, mescaline, 5-MeO-DMT, MDA, and 2-CB.
Agency Having said That it is “committed to ensuring an adequate and uninterrupted supply of controlled substances to meet the estimated legitimate medical, scientific, research and industrial needs of the United States, for legitimate export needs, and to establish and maintain reserve stocks.” ” ,
As such, the 2023 production quota numbers for Psilocene will increase from the original 8,000 grams to 12,000 grams, 5-MeO-DMT from 6,000 to 11,000, MDMA from 8,200 to 12,000 grams, MDA from 200 to 12,000 grams, and 2-CB25. up to 5,100 grams.
In the case of marijuana, the DEA suggested production of 6.7 million grams, or 14,770 pounds, for medical and scientific purposes by 2022. Licensed cultivators can now apply to become federal marijuana suppliers under the National Institute on Drug Abuse. (Nida.)
Several companies have recommended increasing DEA’s 2023 proposed quotas, specifically taking into account pre-clinical and clinical research for PTSD, TRD, schizophrenia, and anxiety.
A comment was received on the proposal regarding the creation of “miscellaneous categories” for the production and research of cannabis (flower), fruiting body extract (similar to cannabis extract), and psilocybin and psilocybin-containing fungus fruiting bodies/sclerotia/liquid culture. Psilocyn isolated as pure compounds (similar to delta-9-THC), as well as mescaline and other plants, fungi, and lifeforms that produce these compounds, apply the same system.
But the agency responded by saying that the suggestions “do not affect the analysis involved in establishing production quotas for each substance”.
Nonetheless, the DEA is listening to what’s happening in the psychedelics space, as it has recently retreated. Banning two psychedelic compounds claimed to have scientific value well as expected Separate project to list five tryptamines as Schedule I substances,
Good luck images and photo courtesy of hermanthos on Shutterstock.